Vistagen Therapeutics, Inc.

What they do

Vistagen develops intranasal pherine product candidates designed to bind peripheral receptors in nasal chemosensory neurons and activate neurocircuits without requiring systemic absorption or brain uptake. Its lead candidate, fasedienol, is in U.S. Phase 3 development for acute treatment of social anxiety disorder. Other candidates include itruvone for major depressive disorder, refisolone for menopausal hot flashes, PH15 for psychomotor impairment due to mental fatigue, and PH284 for cancer cachexia. The company has no approved products and reports no revenue from product sales.

Revenue drivers

• Fasedienol (social anxiety disorder) — Most advanced candidate; in U.S. Phase 3 development with FDA fast track designation for acute treatment of social anxiety disorder. No product revenue; future revenue would depend on regulatory approval and commercialization.
• Refisolone (menopausal hot flashes) — Being developed for moderate to severe vasomotor symptoms due to menopause; received FDA Study May Proceed letter under an open U.S. IND. No product revenue.
• Itruvone (major depressive disorder) — Clinical-stage intranasal pherine candidate for major depressive disorder, one of five in the neuroscience pipeline. No product revenue.
• PH15 and PH284 — Earlier-stage candidates for psychomotor impairment due to mental fatigue (PH15) and cancer cachexia (PH284). No product revenue.

Recent performance

For fiscal year 2026, Vistagen reported revenue of $1.3 million and a net loss of $69.7 million, with operating cash flow of negative $66.4 million. For the fiscal 2027 first quarter ended June 30, 2026, revenue was $1.5 million and cash and cash equivalents were $17.0 million, down from $30.8 million at March 31, 2026. Total assets were $35.7 million and total liabilities were $11.3 million at June 30, 2026. In the quarter, the company reported topline and post-hoc data from PALISADE-4 showing fasedienol did not achieve its primary endpoint in the overall population, though a post-hoc very severe social anxiety subpopulation showed nominally statistically significant improvement versus placebo. Preliminary open-label extension data from PALISADE-3 showed fasedienol was well-tolerated with exploratory efficacy improvement over four months, but the company noted those observations were uncontrolled and should be interpreted with caution.

Strategy

Vistagen is focused on advancing fasedienol toward a potential future Phase 3 path in social anxiety disorder, with FDA engagement planned in the current quarter. The company is also progressing refisolone after receiving an FDA Study May Proceed letter under an open U.S. IND for menopausal hot flashes. Management said it has moved to define next steps, evaluate strategic options and preserve cash since reporting PALISADE-4 results in June. It appointed Angel S. Angelov as Chief Medical Officer and Douglas J. Williamson to the Board, citing their neuroscience drug development experience. The company continues disciplined capital management while supporting its late-stage development programs.

Risks

• Going concern and financing need — The company states it requires substantial additional financing to execute its long-term business plan and to continue to operate as a going concern.
• No approved products or product revenue — Vistagen is a clinical-stage company with no approved products or revenues from product sales and limited experience developing and commercializing product candidates.
• History of significant net losses — The company has incurred significant net losses since inception, including a $69.7 million net loss in fiscal 2026, and expects substantial operating losses for the foreseeable future.
• Clinical and regulatory uncertainty for fasedienol — Fasedienol did not achieve its primary endpoint in the overall PALISADE-4 population, and any future registration path depends on FDA feedback and additional data.

Outlook

Management plans to meet with the FDA in the current quarter regarding a potential future registration-directed development pathway for fasedienol in social anxiety disorder. The company is evaluating strategic options and preserving cash after reporting PALISADE-4 results in June 2026. It also continues development of refisolone following the FDA Study May Proceed letter for menopausal hot flashes. No guidance on product revenue or profitability was provided.